Application of bacteroides intestinalis DSM 17393 strain

Abstract

The invention belongs to the field of application of probiotics and particularly relates to application of a bacteroides intestinalis DSM 17393 strain in preparation of medicines for treating or preventing obesity. According to the invention, C57 / BL6 male SPF-level mice in the same nest are divided into a control group and a strain filling group randomly, a test of filling a bacteroides intestinalis DSM 17393 strain suspension into the stomach is carried out once per day, then the mice are fed with high fat diet, and the test lasts for 7 weeks. The test verifies that the strain is very effective for controlling body weight and body fat, the content of subcutaneous fat of the groin is reduced by 15%, and the content of fat beside the epididymis is reduced by 20.9%. The bacteroides intestinalis DSM 17393 strain can be used for preparing medicines, pharmaceutical compositions, foods and feeds for treating or preventing obesity.

Description

technical field [0001] The invention belongs to the application field of probiotics, in particular to the application of Bacteroides intestinalis DSM17393 bacterial strain in treating or preventing obesity. Background technique [0002] Obesity, as a risk factor for type 2 diabetes, cardiovascular disease and tumors, has become a global social public problem. In the past decade, genome-wide association analysis has discovered more than 100 human obesity susceptibility loci. However, these loci Can only explain a limited number of causes of obesity. Moreover, the current effective treatment methods for obesity are still very limited. Most of the weight-loss drugs approved by the US FDA have been withdrawn from the market due to large side effects or poor effects. It is urgent to develop new weight-loss methods. Another human genome, the gut microbiota genome, is playing an increasingly important role in the development of obesity. Studies have shown that the intestinal flor...

AI Technical Summary

Problems solved by technology

[0002] Obesity, as a risk factor for type 2 diabetes, cardiovascular disease and tumors, has become a global social public problem. In the past decade, genome-wide association analysis has discovered more than 100 human obesity susceptibility loci. However, these loci Explains only a limited portion of obesity pathogenesis

Moreover, the current effective treatment methods for obesity are still very limited. Most of the weight-loss drugs approved by the US FDA have been withdrawn from the market due to large side effects or poor effects. There is an urgent need to develop new weight-loss methods.

Images